Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic ar...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Arthritis Res Ther
Huvudupphovsmän: Brachat, Arndt H., Grom, Alexei A., Wulffraat, Nico, Brunner, Hermine I., Quartier, Pierre, Brik, Riva, McCann, Liza, Ozdogan, Huri, Rutkowska-Sak, Lidia, Schneider, Rayfel, Gerloni, Valeria, Harel, Liora, Terreri, Maria, Houghton, Kristin, Joos, Rik, Kingsbury, Daniel, Lopez-Benitez, Jorge M., Bek, Stephan, Schumacher, Martin, Valentin, Marie-Anne, Gram, Hermann, Abrams, Ken, Martini, Alberto, Lovell, Daniel J., Nirmala, Nanguneri R., Ruperto, Nicolino
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2017
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5260050/
https://ncbi.nlm.nih.gov/pubmed/28115015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1212-x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk